Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Bullish +55

Janney Montgomery Scott LLC Purchases 49,310 Shares of Bristol Myers Squibb Company $BMY - MarketBeat

AI-generated analysis

📈 Janney Montgomery Scott LLC increased its BMY stake by 6.8% in Q1, buying 49,310 shares for a total holding value of $46.7 million.

💰 Bristol Myers Squibb beat earnings expectations with $1.58 EPS and $11.49 billion revenue, surpassing analyst consensus estimates.

📊 The company reported strong profitability metrics including a 15.01% net margin and a 64.87% return on equity.

💵 A quarterly dividend of $0.63 per share was declared, offering a yield of 4.4% to shareholders.

📉 EVP David V. Elkins sold 30,000 shares in early April, reducing his personal position by 15.85%.

🏦 Institutional ownership remains high at 76.41%, with multiple firms like Horizon Bancorp and Cornerstone Wealth increasing stakes.

📝 Analyst ratings are mixed; UBS and Wall Street Zen maintain or upgrade 'buy' ratings, while Bank of America lowered its price target.

🎯 The consensus analyst price target is $61.31, with the stock currently trading at a P/E ratio of 16.14.

📈 Revenue grew 2.6% year-over-year, demonstrating continued top-line growth in the biopharmaceutical sector.

Bullish Signals
  • Bristol Myers Squibb reported earnings per share of $1.58, which beat analyst consensus estimates of $1.42 by $0.16.
  • The company generated revenue of $11.49 billion, exceeding the expected $10.93 billion and showing a 2.6% year-over-year increase.
  • Janney Montgomery Scott LLC increased its position by 6.8%, signaling institutional confidence in the stock's prospects.
  • Wall Street Zen upgraded its rating on BMY from 'buy' to 'strong-buy', reflecting improved analyst sentiment.
  • HSBC raised its price objective for Bristol Myers Squibb from $53.00 to $60.00, indicating a bullish outlook on valuation.
  • The company declared a quarterly dividend of $0.63 per share, providing a 4.4% yield to investors.
Risk Factors
  • EVP David V. Elkins sold 30,000 shares in early April, reducing his personal stake by 15.85%.
  • Bank of America lowered its price objective for Bristol Myers Squibb from $68.00 to $67.00.
  • Citigroup reissued a 'neutral' rating on the stock, contributing to a mixed analyst consensus.
  • The consensus analyst rating is currently 'Hold', suggesting some analysts see limited upside potential at current levels.
Full Analysis
Janney Montgomery Scott LLC increased its stake in Bristol Myers Squibb (NYSE:BMY) by 6.8% in the first quarter, purchasing 49,310 shares to bring total holdings to 770,244 shares valued at approximately $46.7 million. Other institutional investors also adjusted positions, with Horizon Bancorp increasing its stake by 22.1% and several wealth management firms adding new or increased positions, while company insiders own a negligible 0.05% of the stock. Bristol Myers Squibb reported better-than-expected quarterly financial results, posting earnings per share (EPS) of $1.58 against a consensus estimate of $1.42 and revenue of $11.49 billion versus an expected $10.93 billion. The company achieved a net margin of 15.01% and a return on equity of 64.87%, with revenue growing 2.6% year-over-year. Additionally, the firm declared a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record on July 2nd. Analyst sentiment remains mixed but generally positive regarding the company's fundamentals. UBS restated a 'buy' rating, Wall Street Zen upgraded the stock to 'strong-buy', and HSBC raised its price objective from $53.00 to $60.00, though Bank of America lowered its target to $67.00. The consensus analyst rating is currently 'Hold' with an average price target of $61.31, while the stock trades at a P/E ratio of 16.14 and a market capitalization of $117.31 billion.